AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

RecruitingPhase 2Ages 18 Years - 75 YearsAllKeymed Biosciences Co.Ltd
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria: * EASIโ‰ฅ16 at Screening and Baseline visits; * Investigator's Global Assessment (IGA) score ofโ‰ฅ3 at Screening and Baseline visits; * 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits; * Mean of weekly Pruritus Numeric Rating Scale (NRS) severity scoreโ‰ฅ4 at Baseline; Exclusion Criteria: * Not enough washing-out period for previous therapy. * Concurrent disease/status which may potentially affect the efficacy/safety judgement. * Organ dysfunction. * Pregnancy. * Other.
๐Ÿ’Š

What it tests

  • Placebo Comparator
  • CM512
๐Ÿ“

Where

1 site
Peking University People's hospital
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy